Altamira Therapeutics (CYTO): Rasio rega marang prakiraan pendapatan
Altamira Therapeutics (CYTO) minimizes early-stage risks through the licensing of IT solutions and the sale of retail goods. The historical forward P/S allows for an assessment of market expectations, where the value of 4.40 reflects this status. Prospects are bolstered by robotic particle synthesis to accelerate prototyping, while the pristine condition of cleanroom equipment guarantees no downtime in RNA research.
Ringkesan rincian data analitis altamiratherapeutics.com (CYTO)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Altamira Therapeutics|CYTO - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Altamira Therapeutics Ltd.|CYTO - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Altamira Therapeutics|CYTO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Altamira Therapeutics|Indikator likuiditas cepet altamiratherapeutics.com
- indikator pendapatan resik lan kelipatan nilai:
CYTO - Bathi pungkasan|Bathi mangsa ngarep Altamira Therapeutics|CYTO - Rasio rega pasar marang bathi resik|Pangali Forward P/E Altamira Therapeutics Ltd.|CYTO - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Altamira Therapeutics|CYTO - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Altamira Therapeutics|CYTO - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan altamiratherapeutics.com|CYTO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Altamira Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis komprehensif perusahaan:CYTO (Auris Medical)
For Altamira Therapeutics (CYTO), which implements robotic screening and software automation for RNA therapy data, the forward P/S ratio compares the current market value of the business with projected annual sales. This chart allows for an assessment of the extent to which assets are overvalued relative to expected cash flow, where sharp deviations in the forward P/S trend signal speculative pressure or a fundamental reassessment of the company's stability.
Pesaing wigati
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|VRNA - Rasio rega marang prakiraan pendapatan|MENS: Rasio rega marang prakiraan pendapatan|LGND (Ligand Pharmaceuticals) - Multiplikator forward rega marang pendapatan|AMRX: Rasio rega marang pendapatan sing dikarepake|PRGO (Perrigo) - Multiplikator Forward P/S|Multiplikator Forward P/S Alvotech S.A.|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|Multiplikator forward rega marang pendapatan Galapagos Corp GLPG|Multiplikator Forward P/S ANIP (ANI Pharmaceuticals)|Rasio kapitalisasi marang dodolan sing dikarepake mannkindcorp.com (MNKD)|AMPH - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan PCRX (Pacira Pharmaceuticals)|SPRY: Multiplikator Forward P/S|Theravance Corp (TBPH) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan AQST|SCPH: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan TECX (Tectonic Therapeutic, Inc.)|Rasio rega marang pendapatan sing dikarepake TNXP|Multiplikator Forward P/S SXTC (China SXT Pharmaceuticals, Inc.)|Rega forward marang dodolan EPRX|BioHarvest Sciences - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep invizyne.com|oramed.com (ORMP) - Rasio rega marang prakiraan pendapatan|Entera Bio - Rega forward marang dodolan|HYFT (MindWalk) - Multiplikator Forward P/S|Multiplikator Forward P/S ABVC BioPharma, Inc|Rasio rega marang prakiraan pendapatan Cumberland Pharmaceuticals (CPIX)|QNTM: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S FGEN (FibroGen)|Telomir Pharmaceuticals Inc (TELO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RANI: Multiplikator forward rega marang pendapatan|SNYR - Multiplikator Forward P/S|RLYB (rallybio.com) - Multiplikator forward rega marang pendapatan|LEXX: Rasio rega marang pendapatan sing dikarepake|PULM (Pulmatrix) - Multiplikator Forward P/S|Pheton (PTHL) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APM|Multiplikator forward rega marang pendapatan Lyra Therapeutics Inc LYRA|Rasio rega marang prakiraan pendapatan Impact BioMedical Inc IBO|Rasio kapitalisasi marang dodolan sing dikarepake TNF Pharmaceuticals Inc. (TNFA)|cbdMD Corp - Multiplikator Forward P/S|PainReform Ltd (PRFX) - Multiplikator forward rega marang pendapatan|LIPO (Lipella) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Multiplikator forward rega marang pendapatan PIRS|PROC (procapsgroup.com) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|QLI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Rega mangsa ngarep marang pendapatan
